From: Ivins, Bruce E Dr USAMRIID
To: (b) (6)
Subject: CpG and guinea pigs
Date: Thursday, March 16, 2000 8:37:44 AM

Hi (b) (6)

We are currently in the middle of our experiment testing the ability of the CpG oligos to stimulate specific or non-antigen-specific protection against intramuscular anthrax spore challenge in guinea pigs. We currently have no data but here are the groups:

1) These guinea pigs will receive i.m. in the right and left rear thighs 0.05 ml (100 micrograms total) of non-CpG oligonucleotides 6 days before i.m. challenge in the right rear thigh with 100 LD50 of B. anthracis Ames spores. These animals will be the negative controls.

2) These guinea pigs will receive i.m. 100 micrograms (administered as above) of of CpG oligonucleotides 6 days before challenge.

3) These guinea pigs will receive i.m. 100 micrograms (administered as above) of of CpG oligonucleotides 10 days before challenge.

4) These guinea pigs will receive 0.25 ml of AVA human anthrax vaccine in both the right and left rear thighs at 0 and 4 weeks. At 10 weeks, they will be challenged as above.

5) These guinea pigs will receive 0.25 ml of AVA human anthrax vaccine + 0.05 ml of CpG oligos in both the right and left rear thighs at 0 and 4 weeks. At 10 weeks, they will be challenged as above.

6) These guinea pigs will receive 0.25 ml of AVA human anthrax vaccine in both the right and left rear thighs at 0 and 4 weeks. Six days before challenge they will be CpG oligos as above. At 10 weeks, they will be challenged as above.

One week before challenge, all animals will be bled for anti-PA ELISA titers.

Hope this is helpful (b) (6) Any more questions, please contact me.

- Bruce